Celularity Inc (CELU)vsVertex Pharmaceuticals Inc (VRTX)
CELU
Celularity Inc
$1.58
-24.76%
HEALTHCARE · Cap: $21.32M
VRTX
Vertex Pharmaceuticals Inc
$541.69
-1.07%
HEALTHCARE · Cap: $130.59B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 47309% more annual revenue ($12.59B vs $26.55M). VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
CELU
Avoid21
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+72.5%
Fair Value
$4.47
Current Price
$1.58
$2.89 discount
Margin of Safety
+43.3%
Fair Value
$966.04
Current Price
$541.69
$424.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -6367.0% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
The strongest argument for CELU centers on Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CELU profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.54 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 21/100), backed by strong 35.0% margins and 12.5% revenue growth. CELU offers better value entry with a 72.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing a promising pipeline of allogeneic immunotherapies aimed at enhancing treatment outcomes for cancer patients and those with severe medical conditions, while reducing associated complications. With a strong leadership team and strategic partnerships, Celularity is positioned to become a significant force in the dynamic advanced therapeutics sector, addressing critical unmet medical needs and driving advancements in patient care.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?